Detalhe da pesquisa
1.
Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.
Cancer Sci;
115(4): 1114-1128, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38332689
2.
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study.
Cancer Immunol Immunother;
73(1): 4, 2024 Jan 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38175294
3.
Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.
Eur J Clin Pharmacol;
79(4): 503-511, 2023 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36773042
4.
Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study.
BMC Pulm Med;
23(1): 484, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38041137
5.
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Cancer Sci;
113(1): 221-228, 2022 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34704312
6.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Eur Respir J;
60(6)2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35361630
7.
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
Invest New Drugs;
40(5): 1137-1140, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35657573
8.
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.
Invest New Drugs;
40(3): 634-642, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35024985
9.
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.
Invest New Drugs;
40(2): 361-369, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35088212
10.
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.
Invest New Drugs;
39(1): 232-236, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32556898
11.
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
Invest New Drugs;
39(3): 853-859, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33405089
12.
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Invest New Drugs;
39(4): 1106-1112, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33544282
13.
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
BMC Cancer;
21(1): 346, 2021 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33794809
14.
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Invest New Drugs;
38(6): 1854-1861, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32424780
15.
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Invest New Drugs;
38(1): 211-218, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31784866
16.
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
BMC Cancer;
20(1): 93, 2020 Feb 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32013910
17.
Improvement strategies for successful next-generation sequencing analysis of lung cancer.
Future Oncol;
16(22): 1597-1606, 2020 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32490705
18.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Invest New Drugs;
37(6): 1266-1273, 2019 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31392549
19.
Pulmonary carcinosarcoma characterized by small round cells with neuroendocrine, myogenic, and chondrogenic differentiation: An extremely rare case.
Pathol Int;
69(5): 282-287, 2019 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30864171
20.
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Cancer;
124(19): 3830-3838, 2018 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30192383